Agora hosts evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of close to 100 nascent drug targets for AD that were nominated. by AD researchers. The initial list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-AD) consortium. Other evidence presented in Agora was either generated by AMP-AD research teams or is aggregated from publicly available data sources. Future versions of Agora will incorporate other types of -omics evidence as well as target nominations from additional AD research groups.
Agora is funded by the National Institute on Again. It is developed and maintained by Sage Bionetworks.